Householder Group Estate & Retirement Specialist LLC Has $412,000 Holdings in Amgen Inc. (NASDAQ:AMGN)

Householder Group Estate & Retirement Specialist LLC lowered its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 46.0% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 1,584 shares of the medical research company’s stock after selling 1,351 shares during the quarter. Householder Group Estate & Retirement Specialist LLC’s holdings in Amgen were worth $412,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Boston Common Asset Management LLC raised its holdings in Amgen by 3,060.3% in the fourth quarter. Boston Common Asset Management LLC now owns 21,711 shares of the medical research company’s stock worth $5,659,000 after purchasing an additional 21,024 shares during the period. Saxon Interests Inc. raised its stake in Amgen by 4.2% during the 4th quarter. Saxon Interests Inc. now owns 2,074 shares of the medical research company’s stock worth $541,000 after buying an additional 83 shares during the period. Avanza Fonder AB acquired a new stake in Amgen during the 4th quarter worth $15,410,000. Wealthcare Advisory Partners LLC lifted its holdings in Amgen by 3.2% during the fourth quarter. Wealthcare Advisory Partners LLC now owns 13,313 shares of the medical research company’s stock worth $3,470,000 after acquiring an additional 416 shares in the last quarter. Finally, Procyon Advisors LLC grew its stake in Amgen by 4.1% in the fourth quarter. Procyon Advisors LLC now owns 9,748 shares of the medical research company’s stock valued at $2,541,000 after acquiring an additional 385 shares during the period. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on AMGN. Truist Financial dropped their price target on Amgen from $333.00 to $298.00 and set a “hold” rating on the stock in a research report on Wednesday, January 8th. Leerink Partners cut their price target on shares of Amgen from $349.00 to $302.00 in a research note on Wednesday, November 27th. Deutsche Bank Aktiengesellschaft reduced their price target on shares of Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. Piper Sandler Companies restated an “overweight” rating and set a $310.00 price objective on shares of Amgen in a report on Thursday, January 2nd. Finally, Bank of America reaffirmed an “underperform” rating and issued a $256.00 target price on shares of Amgen in a research note on Tuesday, December 10th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Amgen presently has an average rating of “Hold” and a consensus target price of $314.91.

Amgen Stock Performance

Shares of AMGN stock opened at $272.11 on Friday. The company has a fifty day moving average price of $275.01 and a two-hundred day moving average price of $307.49. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85. The stock has a market cap of $146.27 billion, a P/E ratio of 34.84, a P/E/G ratio of 2.68 and a beta of 0.56. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96.

Amgen (NASDAQ:AMGN) last issued its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.11 by $0.47. The business had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. Amgen’s revenue was up 23.2% on a year-over-year basis. During the same period last year, the business posted $4.96 EPS. As a group, equities analysts predict that Amgen Inc. will post 19.57 EPS for the current year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be issued a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, February 14th. This is a positive change from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.50%. Amgen’s payout ratio is presently 115.24%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.